Thai government has just approved the relaxation of issuance of COEs for non-Thai nationals in India to travel to Thailand.
COEs may be issued to non-Thai nationals who are businessmen and experts as per request or approval of the Thai government agencies or Chief Executive Officers (CEOs) of large investment companies in Thailand.
COEs may be issued to non-Thai nationals who are spouses, fathers and mothers, and children of Thai nationals.
COEs may be issued to non-Thai nationals with valid work permits including spouses, fathers and mothers, and children of the said non-Thai nationals.
All of the above-mentioned are subject to the final approval from the relevant Thai authorities.
The Delta variant of Covid-19 has become the dominant strain of Covid-19 in Thailand and has been found in 76 out of 77 provinces.
The Delta variant, first detected in India, is now one of the world’s top concerns due to its 40% higher rate of infection.
The Thai public health department announced another 22,086 new infections to Thailand’s total. 270 of today’s cases stem from the Thai prison system. 217 Covid-related deaths were also announced. 23,672 people were released from hospital care.
60% of people who died in the past 24 hours were 60 years old plus. 18 of the total died at home. The median age of those who died were 65.
According to the Ministry of Public Health, Covid-19 patients in Thailand are taking almost a million Favipiravir pills each day as infection numbers surge around the country. The daily Covid-19 infection rates have now crossed over the 20,000 mark and with so many new cases, the demand for the antiviral tablets is skyrocketing.
Approval was received to begin testing on human subjects in September for a Covid-19 subunit vaccine created in Thailand by the Vaccine Research Centre of Chulalongkorn University and Baiya Phytopharm Company. The vaccine is the second to be racing to clear testing phases and be used to fight Covid-19 in Thailand. The other, an mRNA vaccine, is being developed by Chulalongkorn University with the assistance of Moderna’s Asian distributor Zuellig Pharma